Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial

  1. Oaknin, A.
  2. Moore, K.
  3. Meyer, T.
  4. López-Picazo González, J.
  5. Devriese, L.A.
  6. Amin, A.
  7. Lao, C.D.
  8. Boni, V.
  9. Sharfman, W.H.
  10. Park, J.C.
  11. Tahara, M.
  12. Topalian, S.L.
  13. Magallanes, M.
  14. Molina Alavez, A.
  15. Khan, T.A.
  16. Copigneaux, C.
  17. Lee, M.
  18. Garnett-Benson, C.
  19. Wang, X.
  20. Naumann, R.W.
Journal:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Year of publication: 2024

Volume: 25

Issue: 5

Pages: 588-602

Type: Article

DOI: 10.1016/S1470-2045(24)00088-3 GOOGLE SCHOLAR